Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5702725 | SPECGX LLC | Hydromorphone therapy |
Jul, 2014
(9 years ago) | |
US5914131 | SPECGX LLC | Hydromorphone therapy |
Jul, 2014
(9 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Mar 01, 2013 |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 March, 2010
Treatment: Management of moderate to severe pain
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7691880 | SPECGX LLC | Methylphenidate solution and associated methods of administration and production |
Oct, 2024
(5 months from now) |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: SOLUTION;ORAL